Bayer’s Nexavar heads towards being first compulsory licensing case in India
This article was originally published in Scrip
Executive Summary
India appears to be on course towards considering its first-ever compulsory licence in medicines with the publishing of Natco's request for a compulsory license for Bayer's anticancer, Nexavar (sorafenib tosylate), in the official gazette.